Hope for Parkinson’s disease symptoms is found in late-stage drug study
Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, late-stage study showed that the drug significantly improved the ability of patients to manage daily tasks such as walking and eating.
AbbVie's Parkinson's disease drug meets main goal in late-stage study
AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on Monday. The study tested the safety and efficacy of flexible doses of the drug,
AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study
AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease. Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson's disease.
AbbVie drug succeeds in another Parkinson’s trial
Hello from San Diego, where I always happen to be, but where this weekend I had the delight of hanging out with coworkers including Adam Feuerstein,
AbbVie's Parkinson's disease drug improves patient mobility in late-stage study
AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out daily tasks such as eating and walking, months after the drugmaker disclosed its success in a separate study.
AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal
Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's disease.
AbbVie's Tavapadon Hits Key Goals in Third Phase 3 Parkinson's Study
AbbVie, which in September reported that tavapadon had met the primary and secondary endpoints in a Phase 3 fixed-dose monotherapy trial, said it is on track to file for Food & Drug Administration approval of the drug in 2025. AbbVie picked up tavapadon as part of its $8.7 billion acquisition of Cerevel Therapeutics earlier this year.
BlackDoctor2d
Oschner Health Is Taking on First-of-Its-Kind Black Parkinson’s Research
The new Ochsner site will contribute to uncovering additional genes as well as examine health disparities and care access for ...
Reuters7d
In paraquat lawsuits, an expert gets bumped (again)
The late November decision by a judge in Contra Costa County ... science-based review of regulatory authorities” have not ...
AbbVie’s third successful Parkinson’s trial sets the stage for an eventful 2025
AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson’s disease on Monday and said it’s on track to seek approval for the drug from the Food and Drug ...
unilad6d
Michael J. Fox gives Parkinson's disease update ahead of Back to the Future's 40th anniversary
Michael J Fox has given an honest update on how he copes with Parkinson's disease. The star is best known for playing Marty ...